Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Shire recalls some Daytrana shipments
Mom, I can't get my ADHD patch on! Shire is recalling some lots of Daytrana, its attention deficit hyperactivity disorder patch--not because of safety issues, but because patients are having a hard time removing the release liner so they can administer the drug. The withdrawal is expected to cost the British drug maker some $10 million.
- see this release
- here's the report from MarketWatch
Related Articles:
FDA approves Daytrana ADHD patch. Report
FDA signals a quick approval for Shire's ADHD drug. Report
CDC estimates reignite ADHD controversy. Report
Be the first to comment
More stories about Controversy
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
